

Akums launches drug combo for Type-2 Diabetes

Dapagliflozin and Pioglitazone tablet combo is taken once daily, providing a dual-action approach to managing type 2 diabetes and simplifies the overall management of the condition.



New Delhi: Expanding its portfolio from manufacturing to marketing drugs, a CDMO Akums Drugs and Pharmaceuticals, has launched Dapagliflozin + Pioglitazone tablets; an advanced combination

therapy indicated for the management of Type-2 diabetes.

The DCGI approved dual-action formulation offers a more potent solution for individuals struggling with existing metformin-based regimens and it goes beyond glycemic control, overcoming broader obstacles associated with diabetes care, the company stated.

Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids in eliminating excess glucose via urine whereas, Pioglitazone, is a thiazolidinedione which augments insulin sensitivity in key tissues, such as muscles and the liver, helping combat the root issue of insulin resistance.

Commenting on the launch, Sandeep Jain, Managing Director of Akums Drugs and Pharmaceuticals, said, “The rise in diabetes cases in our country calls for novel and accessible solutions and.. requires a collaborative effort between healthcare providers and pharmaceutical innovators. The launched Dapagliflozin + Pioglitazone tablets is a dual-action therapy developed to progress patient outcomes and overall well-being.”

As per an analysis by a market research firm Phamarack, till October 2024 the Indian anti-diabetic drug market was valued around ₹17,000 crore and in a realistic scenario it is projected to expand at a CAGR of 6.5 per cent.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/akums-launches-drug-combo-for-type-2-diabetes/117884021>